This site contains promotional information intended only for healthcare professionals resident in Great Britain

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutAboutConjugate TechnologyPneumococcal DiseaseDosing & AdministrationDosing & AdministrationDosing, Administration & StoragePrevious Pneumococcal VxClinical Trial ProgrammeClinical Evidence & SafetyClinical Trial ProgrammeSafety ProfilePrivate Vaccination Service Private Vaccination ServiceIdentifying Those at Increased Risk of Pneumococcal Pneumonia

The content of this site is based on the Prescribing Information for APEXXNAR®▼ (pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)) for Great Britain. The Prescribing Information for Great Britain can be found here. Prescribing Information for Prevenar 13® (pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)) can be found here.

Identifying Those at Increased Risk of Pneumococcal Pneumonia

Pneumonia can be caused by bacteria, viruses and fungi1. Streptococcus pneumoniae is the most common bacterial cause1
 

APEXXNAR Private Vaccination Service

Adults can choose to pay privately to receive APEXXNAR in the UK to help protect themselves from invasive disease and pneumonia caused by Streptococcus pneumoniae2.

APEXXNAR can be administered privately at any time of year2.

Learn more about APEXXNAR ⇒Loading
UK National Immunisation Programme

Alternative pneumococcal vaccines are available as part of the UK National Immunisation Programme for specific patient cohorts at increased risk of serious illness3.

This includes; babies, adults aged 65 years and older, and children and adults with specific long-term health conditions3.

Full NIP Schedule in the Green Book, Chapter 25 ⇒Loading

Learn About Your Patients

Watch these videos about how some conditions can increase the risk of developing pneumococcal disease.

Click to watch a video about
Badge
Click to watch a video about
Badge
Click to watch a video about
Who might be at increased risk of pneumococcal pneumonia?

Pneumonia can affect people of any age1. However, many factors can put adults at increased risk of pneumococcal infections, including pneumococcal pneumonia, making them potential candidates for private vaccination1,4-13.

Those who might be at increased risk include:

  • Aged>45 years: The risk of contracting pneumococcal pneumonia increases from the age of 45 onwards4,5.
  • Smoking: Smokers are 4.4 times* more likely to develop pneumonia than someone who has never smoked6.
  • Exposure to lots of people in close contact7: This could include the Hajj and Umrah pilgrimages. For example, a 2.7 fold increase in nasal carriage rate of Streptococcus pneumoniae was reported in pilgrims returning from Hajj in 20128.
  • Travelling: Many of the world’s most popular tourist destinations9, including South Asia and parts of Africa are also home to higher levels of pneumococcal infections10. Some countries, like China and Thailand, do not routinely immunise against pneumococcal disease11.
  • Those who have already had pneumonia : People who have had pneumonia in the past are twice as likely to get pneumonia again compared with people who have never had pneumonia12.
  • Those with a flu infection: During a flu infection, and for up to one week after, you are around 100 times more likely to develop pneumococcal pneumonia13.
  • Chronic conditions including respiratory disease, heart disease, diabetes, liver disease, kidney disease3,6 and asthma6:
    • The increased likelihood of developing pneumococcal pneumonia compared to a healthy person6:

*Risk data above is for people aged 50-64. People aged 18-49 had lower risk ratios and people 65 years and older had higher ratios. 

Risk factors for pneumococcal disease

Watch these videos to learn more about how these chronic conditions can be risk factors for pneumococcal disease.

Watch this video on chronic heart disease and pneumococcal disease 

Identify a Patient

Learn about how chronic heart disease can be a risk factor for pneumococcal disease in this three and a half minute video12.

Button Loading

Watch this video on chronic respiratory disease and pneumococcal disease

Identify a Patient

This four minute video informs about how chronic respiratory disease can be a risk factor for pneumococcal disease12

Button Loading

Watch a video on diabetes and pneumococcal disease

Identify a Patient

A diagnosis of diabetes is a risk factor for pneumococcal disease12. Learn more in this three minute video.

Button Loading

APEXXNAR can be administered privately at any time of year2

Opportunities to identify candidates for private vaccination services can occur all year round.
Explore our content to learn more about APEXXNAR
.
 

About APEXXNAR

20-valent pneumococcal conjugate vaccine for adults that helps protect against pneumococcal disease originating from vaccine-type serotypes2,14

Back to Home→ Loading

Your guide to conjugate vaccine technology

Find out about the composition of conjugate vaccines2 

 

How it works →Loading

Key information on APEXXNAR

Key information about dosing, administration and storage of APEXXNAR2

Learn more →Loading

References:

Asthma and Lung UK. What is pneumonia. Available at: https://www.asthma.org.uk/conditions/pneumonia/what-is-it. Last accessed March 2024.APEXXNAR (Pneumococcal polysaccharide conjugate vaccine [20-valent, adsorbed]). Summary of Product Characteristics.UK Health Security Agency. The Green Book (published 2013; updated 2023) Chapter 25: Pneumococcal. Available at: https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25. Last accessed March 2024.Miller E,  Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. LancetInfectDis 2011;11:760-768.Pick H, Daniel P, Rodrigo C, et al. Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18. Thorax Epub 2020;75:38–49.Shea KM, Edelsburg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open forum Infect Dis. 2014;1-9.Centres for Disease Control and Prevention. Pneumococcal Disease. Transmission. Available at: https://www.cdc.gov/pneumococcal/clinicians/transmission.html . Last accessed March 2024.Benkouiten S, Gautret P, Belhouchat K, et al. Acquisition of Streptococcus pneumoniae carriage in pilgrims during the 2012 Hajj. Clin Infect Dis. 2014;58(4):e106-9. World Tourism Organisation. International tourism highlights 2023. Available at: https://tourismecotedivoire.ci/wp-content/uploads/2023/12/Tourism-Highlights.pdf. Last accessed March 2024. Ferreira D, Jambo KC, Gordon SB. Experimental human pneumococcal carriage models for vaccine research. Trends Microbiol. 2011;19(9):464-70.International Vaccine Access Centre (IVAC), View-hub. Pneumococcal conjugate vaccine introduction and use. Available at: https://www.view-hub.org/vaccine/pcv. Last accessed March 2024.Almirall J, Bolíbar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J. 2008 Jun;31(6):1274-84.Shrestha S, Foxman B, Berus J, et al. The role of influenza in the epidemiology of pneumonia. Sci Rep. 2015 May 22;5:15314.Prevenar 13 GB (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]). Summary of Product Characteristics GB.
PP-PNR-GBR-0157. March 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​